Deletions of CDKN2C in multiple myeloma: Biological and clinical implications

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6033-6041

  Leone, Paola E ^a   Walker, Brian A ^a   Jenner, Matthew W ^a   Chiecchio, Laura ^b   Dagrada, Gianpaolo ^b   Protheroe, Rebecca K M ^b   Johnson, David C ^a   Dickens, Nicholas J ^a   Brito, Jose Luis ^a   Else, Monica ^a   Gonzalez, David ^a   Ross, Fiona M ^b   Chen Kiang, Selina ^c   Davies, Faith E ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Leukaemia Research Fund UK Myeloma Forum Cytogenetics Group   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2C; CDKN2C PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME DELETION; CLINICAL FEATURE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MAPPING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METHYLATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; AGED; BIOLOGICAL MODEL; CHROMOSOME MAP; DISEASE COURSE; GENE DELETION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; METHODOLOGY; MIDDLE AGED; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

AGED; CELL LINE, TUMOR; CHROMOSOME MAPPING; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DISEASE PROGRESSION; GENE DELETION; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MODELS, GENETIC; MULTIPLE MYELOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149166787     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0347     Document Type: Article

References (31)

1. Morse L, Chen D, Franklin D, Xiong Y, Chen-Kiang S. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity 1997;6:47-56.
2. Cox C, Bignell G, Greenman C, et al. A survey of homozygous deletions in human cancer genomes. Proc Natl Acad Sci U S A 2005;102:4542-7.
3. Avet-Loiseau H, Andree-Ashley LE, Moore D II, et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 1997;19:124-33.
4. Cigudosa JC, Rao PH, Calasanz MJ, et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998;91:3007-10.
5. Nilsson T, Hoglund M, Lenhoff S, et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 2003;120:960-9.
6. Liebisch P, Viardot A, Bassermann N, et al. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. Br J Haematol 2003;122:193-201.
7. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003;17:427-36.
8. Liebisch P, Wendl C, Wellmann A, et al. High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis. Leukemia 2003;17:2535-7.
9. Gutierrez NC, Garcia JL, Hernandez JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004;104:2661-6.
10. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005;44:194-203.
11. Marzin Y, Jamet D, Douet-Guilbert N, et al. Chromosome 1 abnormalities in multiple myeloma. Anticancer Res 2006;26:953-9.
12. Schultheis B, Kramer A, Willer A, Hegenbart U, Goldschmidt H, Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia 1999;13:2099-103.
13. Hayami Y, Iida S, Nakazawa N, et al. Inactivation of the E3/LAPTm5 gene by chromosomal rearrangement and DNA methylation in human multiple myeloma. Leukemia 2003;17:1650-7.
14. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinicopathogenetic subgroups ofmultiplemyeloma patients. Cancer Cell 2006;9:313-25.
15. Walker BA, Leone PE, Jenner MW, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006;108:1733-43.
16. Kulkarni MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, Williams ME. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 2002;16:127-34.
17. Dib A, Peterson TR, Raducha-Grace L, et al. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div 2006;1:23.
18. Tasaka T, Berenson J, Vescio R, et al. Analysis of the p16INK4A, p15INK4B and p18INK4C genes inmultiple myeloma. Br J Haematol 1997;96:98-102.
19. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-11.
20. Ross FM, Ibrahim AH, Vilain-Holmes A, et al. Age has a profound effect on the incidence and significance of chromosome abnormalities inmyeloma. Leukemia 2005;19:1634-42.
21. Wuilleme S, Robillard N, Lode L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 2005;19:275-8.
22. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-7.
23. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004;20:1233-40.
24. Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005;65:6071-9.
25. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97.
26. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J, Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303.
27. Sanchez-Aguilera A, Delgado J, Camacho FI, et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 2004;103:2351-7.
28. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8.
29. Cook WD, McCaw BJ. Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene 2000;19:3434-8.
30. Bai F, Pei XH, Godfrey VL, Xiong Y. Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis. Mol Cell Biol 2003;23:1269 - 77.
31. Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005;65:11345-53.